DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ℹ️ Observational Association Only Evidence
Researchers applied two-sample Mendelian randomization to GWAS data from more than 220,000 individuals to evaluate genetically predicted causal associations between 40 drugs and erectile dysfunction. Six agents — two statins, an ACE inhibitor, two antidiabetics, and a beta-blocker — showed associations with ED risk after confounding SNP exclusions. The analysis is the first to use MR methodology across multiple drug exposures simultaneously for ED.
Clinical Considerations
- Genetically predicted associations with ED were identified for simvastatin, atorvastatin, ramipril, metformin, gliclazide, and atenolol; aspirin did not reach significance (p=0.051) after SNP adjustment
- Atenolol and metformin produced implausibly high odds ratios, which the authors attribute to possible weak instrument bias, low event counts, or rare variant influence so interpret with caution
- Findings apply exclusively to a European population (n=223,805); generalizability to other ancestries remains unknown
- Authors acknowledge ED risk in these patients may reflect pharmacodynamic effects, underlying comorbidities, or psychological factors rather than direct drug causation
Practice Applications
- Recognize this as hypothesis-generating MR evidence. Genetically predicted associations require RCT validation before informing prescribing decisions or patient counseling.
- Consider proactive ED screening conversations with male patients initiating or maintained on statins, ACE inhibitors, beta-blockers, or oral antidiabetics, independent of this study’s conclusions
- Avoid attributing ED causally to specific agents in this list without ruling out disease burden, metabolic comorbidities, and psychological contributors
- Monitor for RCT-level evidence as this MR signal may inform future trial design around ED as a secondary outcome in cardiovascular and metabolic drug studies
